In a second step, we evaluated the efficacy of our treatment strategy in a more systematic setting by inoculating luciferase-expressing A-673 cells intraperitoneally and repeatedly injecting GPR64-directed, 2.2-pseudotyped lentivirus expressing HSV-TK (pLenti_25_TK) or PBS (negative control) into the peritoneal cavity 3 days after tumor inoculation. This evidence concerns the gene ADGRG2 and neoplasm.